Pralsetinib plus leucogen for RET fusion-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a targeted pill called pralsetinib given together with a supportive medicine (leucogen) for people whose lung cancer has a specific RET gene change. The goal is to see how well this combination works in everyday hospital care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung cancer called adenocarcinoma that has spread and cannot be removed by surgery.
- Your cancer has a specific genetic change called a RET fusion.
- You have never had treatment for your lung cancer before.
- Your blood counts and liver/kidney function are good enough (they will test this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted pill (Firmonertinib) combined with chemotherapy before surgery for people with early to mid-stage non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.